Abbott next-gen continuous glucose monitor now available to Medicare
Abbott (NYSE:ABT) announces Medicare coverage of its next-generation FreeStyle Libre 2 continuous glucose monitoring system. The device measures blood sugar levels every minute via a sensor worn on the back of the upper arm for up to 14 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.